CRE RESPOND is a $2.5 million multi-institutional collaborative funded by the National Health and Medical Research Council of Australia from 2021 – 2026 to reduce the burden of antimicrobial resistance through optimal personalised dosing. It aims to bring about new findings from research and share these with clinicians so that they can provide better treatment to their patients and improve outcomes for them and their families.
Infection causes unacceptably high morbidity and mortality worldwide. It is common for Australian clinicians to be confronted by patients who are infected by pathogens that are resistant to all available antimicrobials.
CRE RESPOND will address antimicrobial resistance and unacceptably poor patient outcomes with evidence-based personalised antimicrobial drug dosing.
The CRE will achieve this through a large body of work to generate new knowledge that will change policy and practice to improve patient and health system outcomes and build research capacity to make further gains in personalizing dosing and reducing antimicrobial resistance.
CRE RESPOND aims to:
-Generate new knowledge that leads to improved health outcomes
-Promote effective transfer of research outcomes into health policy and/or practice
-Develop the health and medical research workforce by providing opportunities to advance the training of new researchers, particularly those with a capacity for independent research and future leadership roles
-Facilitate collaboration
Company Details
- Employees
- 1
- Founded
- -
- Address
- Uq Ccr, Herston,qld 4006,australia
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Keywords
- Infectious diseases, Pharmacokinetics, Antimicrobial Optimisation, Research, Pharmaceuticals, Personalised medicine, Therapeutics, Critical care medicine, Antimicrobial resistance, Antibiotics, Antifungals, Antivirals, Respiratory medicine, Bioanalysis, Burns patients, Transplant medicine, Antibiotic administration, Drug monitoring, Dose personalisation, Clinical practice guidelines, Clinical trials, Clinical research, Pharmacometric analysis, Microsampling, Therapeutic drug monitoring, Clinical dosing.
- HQ
- Herston, QLD
- Competitors
- Inia Health / MindCheck, De Groot Technical Services, Pelvic Pain Foundation of Australia, The National Centre for Infections in Cancer, Novoviah - Ultra-sensitive T cell testing in patients, Funky Fungus, Hospital in the Home Society of Australasia, Bioessence Consultancy Services, Zucero Therapeutics Ltd, Jetra Therapeutics.
Cre Respond Questions
Cre Respond's website is https://cre-respond.centre.uq.edu.au/
Cre Respond's LinkedIn profile is https://au.linkedin.com/company/cre-respond
Cre Respond has
1 employees.
View email and phone details for 1
employees at Cre Respond.
Cre Respond's industry is
Research Services
Cre Respond's top competitors are
Inia Health / Mindcheck,
De Groot Technical Services,
Pelvic Pain Foundation Of Australia,
The National Centre For Infections In Cancer,
Novoviah - Ultra-Sensitive T Cell Testing In Patients,
Funky Fungus,
Hospital In The Home Society Of Australasia,
Bioessence Consultancy Services,
Zucero Therapeutics Ltd,
Jetra Therapeutics.
Cre Respond's categories are Research Services
Cre Respond's founding year is 2016
